Difficulty: Medium
Average Score: 86%
Practice
Which of the following drugs have no mortality benefit?
Correct answer
C
Rationale
In the context of pediatric nursing and cardiovascular disorders, understanding the pharmacological treatment options is crucial. In this question, the correct answer is C) Trimetazidine, as it is the only drug among the options that has no mortality benefit in cardiovascular disorders.
Trimetazidine is primarily used to improve angina symptoms by optimizing myocardial metabolism but does not show any significant impact on reducing mortality. Nitrates (option A), beta-blockers (option B), and RAAS blockers (option D) are all known to have mortality benefits in various cardiovascular conditions.
Nitrates help dilate blood vessels, improving blood flow and reducing cardiac workload. Beta-blockers are essential in managing conditions like heart failure and hypertension, reducing mortality by their effects on the heart rate and contractility. RAAS blockers play a crucial role in conditions like heart failure and hypertension by modulating the renin-angiotensin-aldosterone system, thereby improving outcomes and reducing mortality.
Understanding the mortality benefits of different drug classes in pediatric cardiovascular disorders is vital for nurses caring for these patients. It enables them to make informed decisions in drug therapy selection, monitor for outcomes, and educate patients and families on the rationale behind the prescribed medications. This knowledge ultimately contributes to providing comprehensive and effective care to pediatric patients with cardiovascular disorders.
Trimetazidine is primarily used to improve angina symptoms by optimizing myocardial metabolism but does not show any significant impact on reducing mortality. Nitrates (option A), beta-blockers (option B), and RAAS blockers (option D) are all known to have mortality benefits in various cardiovascular conditions.
Nitrates help dilate blood vessels, improving blood flow and reducing cardiac workload. Beta-blockers are essential in managing conditions like heart failure and hypertension, reducing mortality by their effects on the heart rate and contractility. RAAS blockers play a crucial role in conditions like heart failure and hypertension by modulating the renin-angiotensin-aldosterone system, thereby improving outcomes and reducing mortality.
Understanding the mortality benefits of different drug classes in pediatric cardiovascular disorders is vital for nurses caring for these patients. It enables them to make informed decisions in drug therapy selection, monitor for outcomes, and educate patients and families on the rationale behind the prescribed medications. This knowledge ultimately contributes to providing comprehensive and effective care to pediatric patients with cardiovascular disorders.